؉ T cells exist in normal individuals and retain the capacity to initiate autoimmune disease. The current study investigates the role of CD4 ؉ CD25 ؉ T-regulatory (T R ) cells during autoimmune disease using the CD4 ؉ T cell-dependent myelin oligodendrocyte glycoprotein (MOG)-specific experimental autoimmune encephalomyelitis model of multiple sclerosis. In vitro, T R cells effectively inhibited both the proliferation of and cytokine production by MOG 35-55 -specific Th1 cells. In vivo, adoptive transfer of T R cells conferred significant protection from clinical experimental autoimmune encephalomyelitis which was associated with normal activation of autoreactive Th1 cells, but an increased frequency of MOG 35-55 -specific Th2 cells and decreased CNS infiltration. Lastly, transferred T R cells displayed an enhanced ability to traffic to the peripheral lymph nodes and expressed increased levels of the adhesion molecules ICAM-1 and P-selectin that may promote functional interactions with target T cells. Collectively, these findings suggest that T R cells contribute notably to the endogenous mechanisms that regulate actively induced autoimmune disease.
A n essential characteristic of intrathymic CD4
ϩ T cell development is the generation of TCR diversity which permits T cells to respond to a huge number of foreign Ags. However, one consequence of TCR diversity is the inevitable emergence of autoreactive T cell populations that persist in normal individuals with the capacity of mediating various autoimmune diseases (1) . To combat this, regulatory cell populations and other protective mechanisms, such as clonal deletion and activation-induced anergy, have evolved with the collective goal of inhibiting the generation and/or function of autoreactive CD4 ϩ T cells. CD4
ϩ T-regulatory (T R ) 3 cells display a mixed phenotype of naive and activated cell surface markers, e.g., CD4
ϩ CD25 ϩ CD62L high (2) . Importantly, the T R cell population does not contain previously activated CD4 ϩ T cells (3) and inhibits T cell proliferation in a TCR-dependent manner, possibly via direct T-T cell interactions. Although the exact mechanism by which T R cells exert their inhibitory influence is still unknown, IL-10 production, surface CTLA-4 expression, IL-2 binding, costimulatory molecule blockade, and surface TGF-␤ expression are all proposed mechanisms by which T R cells may down-regulate CD4 ϩ T cell responses (2) .
Consistent with their proposed role as active regulators of autoimmune responses, the depletion of T R cells in neonatal animals results in the spontaneous induction of autoimmune gastritis in both the thymectomy and nu/nu model systems (4, 5) . Importantly, T R cells also block the gastritis resulting from the transfer of H/K ATPase-specific effector T cells (4, 5) . Similarly, the transfer of CD4 ϩ CD25 ϩ T R cells in an adoptive model of diabetes conferred significant protection against the onset of spontaneous diabetes (6) , and transfer of either CD4 ϩ CD25 Ϫ or CD4 ϩ CD25 ϩ T R cells has been reported to suppress spontaneous experimental autoimmune encephalomyelitis (EAE) mediated by naive myelin basic protein (MOG)-specific T cells in recombination-activating gene-1-deficient TCR-transgenic mice (7, 8) . Collectively, these findings suggest that T R cells may block both the initiation of autoimmune responses and inhibit the function of established autoreactive effector cells.
In this study, we investigate the role of T R cells in regulating the progression of active EAE in conventional C57BL/6 mice. MOG 35-55 -specific EAE (9), a mouse model of multiple sclerosis, is a CD4 ϩ Th1-mediated autoimmune disease (10) in which autoreactive T cells specific for myelin components enter the CNS, initiating a cascade of inflammation and demyelination. We report here that CD4 ϩ CD25 ϩ T R cells inhibit both the proliferation of and IFN-␥ production by a MOG 35-55 -specific T cell line in vitro. In addition, supplementation of T R cell numbers by adoptive transfer before active and adoptive EAE induction significantly reduced the severity of clinical disease potentially by promoting a diseaseprotective Th2 immune response and preventing CNS inflammation via a mechanism that may involve up-regulated expression of ICAM-1 and P-selectin. Together, these findings support a role for T R cells in protection from the onset/progression of autoimmune demyelination in wild-type mice induced by active MOG 35-55 / CFA immunization or adoptive transfer of differentiated autoreactive Th1 cells.
Materials and Methods

Mice
Female C57BL/6 mice, 5-6 wk old, were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained on standard laboratory food and water ad libitum. Paralyzed animals were afforded easier access to food and water.
T R cells
Peripheral lymph nodes (LNs) were harvested from 6-to 7-wk-old mice, mechanically disassociated, and depleted of APC populations before positive selection of CD25 ϩ T R cells using anti-CD25 Ab (7D4), anti-rat microbeads (Miltenyi Biotec, Auburn, CA), and an AutoMACs (Miltenyi Biotec). The resulting population consisted of between 85 and 95% CD4 ϩ CD25 ϩ CD62L high T cells. 6 T R (CD25 ϩ ) or non-T R (CD25 Ϫ ) cells into naive C56BL/6 mice (11). Individual animals were observed daily, and clinical scores were assessed in a blinded manner on a scale of 0 -5 as follows: 0 ϭ no abnormality; 1 ϭ limp tail; 2 ϭ limp tail and hind limb weakness; 3 ϭ hind limb paralysis; 4 ϭ hind limb paralysis and forelimb weakness; and 5 ϭ moribund. Data are reported as the mean daily clinical score. Mice were age and sex matched for all experiments.
In vitro proliferation and ELISPOT assay
Induction and clinical evaluation of MOG 35-55 -induced EAE
Immunohistochemistry and immunofluorescence
CNS immunohistochemistry was performed as previously described (11) . For immunofluorescence, single-cell suspensions were washed and incubated with fluorescently tagged Abs directed against a panel of cell surface markers (BD PharMingen, San Diego, CA). Fluorescent staining was analyzed using a FACSCalibur and CellQuest Pro (BD Biosciences, San Jose, CA).
Statistical analysis
Comparisons of clinical scores and ELISPOT frequencies between the various treatment groups were analyzed by unpaired Student's t test. Values of p Ͻ 0.01 were considered significant.
Results
CD4
ϩ CD25 ϩ T R cells suppress the proliferation of both CD4 ϩ and CD8 ϩ T cells; however, the exact mechanism by which these cells exert their effector function remains elusive. To elucidate the potential of T R cells for regulating the induction and/or progression of EAE, we first determined whether T R cells could suppress the in vitro proliferation of a T cell line (11) specific for an immunodominant epitope of MOG (MOG 35-55 ) known to initiate EAE in C57BL/6 mice. As seen in Fig. 1A , coculture of a fixed number of a MOG 35-55 -specific Th1 line with an increasing number of T R cells isolated from naive C57BL/6 mice inhibited the level of T cell proliferation, regardless of whether the T R cells were isolated from either the LN or spleen. Overnight culture of LN T R cells with recombinant IL-2, before coculture with target cells, also had no observed effects on suppressive function. In addition to effects on cellular proliferation, T R cells (E:T ratio, 2:1) also reduced the level of IFN-␥ secreted by the MOG 35-55 -specific Th1 cell line (Fig. 1B) , which is the predominant cytokine produced by this line as determined by gene array analysis (data not shown). As with cellular proliferation, T R -mediated suppression of IFN-␥ production was directly proportional to the E:T ratio (data not shown). Thus, T R cells appear to be competent in suppressing MOG 35-55 -specific T cell proliferation and IFN-␥ production in vitro.
On the basis of the above findings, we next investigated the role of T R cells in modulating EAE disease progression in vivo. First, T R cells were isolated from LNs of naive C57BL/6 donors, and 2 ϫ 10 6 T R cells were adoptively transferred into naive recipients 3 days before active induction of EAE. Supplementation of T R cells conferred significant protection from the development of clinical EAE ( Fig. 2A) , in comparison with mice receiving either no cells or non-T R CD4 ϩ T cells. Surprisingly, the number of cells secreting disease-promoting Th1 cytokines, such as IFN-␥ and TNF-␣ (12), were similar in the LNs (Fig. 2B ) and spleens (data not shown) at the peak of disease in all groups of mice. Of potential importance, the number of MOG 35-55 -specific IL-2-secreting cells was significantly diminished (Fig. 2C) , and the number of IL-4 and IL-5-secreting cells was elevated in regulatory cell recipients (Fig. 2, D and E) . Lastly, we examined the capacity of T R cells to regulate the effector function of previously activated autoreactive T cells by coinjecting T R or non-T R cells with MOG 35-55 -specific T cell blasts. Clinical symptoms in mice receiving T R cells were reduced by ϳ50% in comparison with mice receiving non-T R cells (Fig. 2F) . Thus, supplementation of T R cell numbers conferred protection against both active and passive EAE disease progression, in the absence of any observable effect on the frequency of T cells producing disease-promoting cytokines, whereas the number of cells secreting disease-protective Th2 cytokines was elevated.
As previously discussed, CNS inflammation is a characteristic of EAE disease progression. The degree of lymphocyte infiltration correlates with both the level of macrophage infiltration/activation and disease severity (13) . In agreement with this, CD4 ϩ T cell infiltration and F4/80 ϩ APC activation/infiltration was substantially reduced in the spinal cords of T R recipients (Fig. 3) despite the normal frequency of peripheral MOG 35-55 -specific Th1 cells. These findings raised the possibility that T R cells may enter the CNS to locally regulate immune cell activation and inflammation. To address this possibility, we examined the peripheral lymphoid organs and CNS tissues of individual mice for the presence of the transferred T R cells. Although the number of non-T R CD4
ϩ T cells was markedly reduced 6-to 12-fold within the CNS of T R cell recipients (Fig. 4A) , we failed to detect the transferred T R cell population within either the brain or spinal cord during the peak of EAE. In contrast, there were 3.5-fold more donor cells in the LNs 
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CUTTING EDGE: CD4 ϩ CD25 ϩ T R CELLS PROTECT AGAINST EAE PROGRESSION of T R vs non-T R recipients, suggesting differential trafficking of these populations. This finding may be explained by differential adhesion molecule expression on T R cells, which expressed elevated levels of both surface P-selectin (CD62P) and ICAM-1 (Fig.  4B) . Therefore, T R cells appear to confer protection to mice against progression of EAE by a mechanism involving enhanced Th2 cytokine production and inhibition of CNS inflammation, which may be dependent on expression of specific adhesion molecules.
Discussion
It is currently believed that TCR ligation enables T R cells to nonspecifically inhibit CD4 ϩ T cell proliferation both in vitro and in vivo (3). However, there is a surprising deficiency in the literature concerning the effects of T R cells on additional functional measures such as cytokine production and cellular differentiation. We report that coculture of MOG 35-55 -specific T cells with T R cells inhibits the level of both Ag-specific proliferation and IFN-␥ production. T R cells appear not to prevent the initial activation of target CD4 ϩ T cells but subsequently induce cell cycle arrest (3). In light of these findings, it is not clear whether the measured reduction in IFN-␥ production is the result of direct effects on cytokine production or whether it results from inhibition of Agspecific cell expansion. Previous studies indicate that T R cells must be activated via TCR ligation before exerting their immunosuppressive phenotype (14) ; however, the limiting frequency of MOG 35-55 -specific T R cells undoubtedly present in our in vitro culture system suggests that T R cells are more efficient inhibitors of Ag-specific than mitogen-induced T cell responses and/or that these cells become activated as a result of the isolation process.
To investigate the role of T R cells in regulating the progression of autoimmune diseases, we used a model system in which the T R cell population in naive C57BL/6 mice was supplemented before both active and passive induction of EAE. Augmentation of T R cell numbers by ϳ50 -75% (2 ϫ 10 6 T R cells transferred to naive recipients normally containing an estimated 2.5-3 ϫ 10 6 T R cells) conferred significant protection against EAE induction/progression as measured by both disease score and the promotion of protective Th2 cytokines. In addition, we observed markedly less CD4 ϩ T cell infiltration into the CNS at the peak of disease in T R cell recipients which corresponded with decreased levels of APC infiltration/activation within the CNS (Fig. 3) . One explanation of these findings is that T R cells inhibit the expansion of MOG-specific T cells in peripheral lymphoid organs. This possibility is supported by the decreased frequency of MOG 35-55 -specific IL-2-producing cells in T R cell recipients, but not by the normal numbers of Ag-specific IFN-␥ ELISPOTs (Fig. 2) . Alternatively, we detected an increased frequency of cells producing Th2-like cytokines in the LNs and spleens of T R cell recipients after disease initiation. Therefore, it is possible that T R cells differentially influence either the differentiation or effector function of Th1 and Th2 cells, with the normal frequency of Th1 cells better supporting the latter possibility. In addition, the elevated number of MOG 35-55 -specific Th2 cells in T R recipients may result from inhibition of the pathogenic Th1-like responses, subsequently allowing the progression of bystander Th2 responses. This possibility is further supported by our findings that mitogenic (anti-CD3 Ab) simulation of LN and spleen cells isolated from T R recipients induced a significant increase in the number of cells producing Th2-like cytokines in comparison with cells stimulated with the specific MOG 35-55 peptide (Fig. 2) . However, further study is necessary to gain a better understanding of the exact effector mechanisms of T R cells during EAE disease progression.
Little is currently known about the homing patterns and site(s) of T R cell function in vivo. During EAE, T R cells may traffic to the CNS to inhibit the local activation of myelin-specific autoreactive T cells, a prerequisite for development of inflammatory demyelination (11) . However, we failed to detect donor T R within the CNS at a time corresponding with the peak of disease in non-T R cell recipients (Fig. 4A) , whereas T R cell populations were detectable in recipient spleen and LNs. This finding supports the hypothesis that T R cells may influence the activation of autoreactive T cells within peripheral lymphoid organs and/or the homing of activated lymphocytes to the CNS. This latter hypothesis gains further support from current findings (Fig. 2F) and those of others (4, 5) showing that T R cells inhibit the in vivo function of previously activated T cells. It is possible that the numbers of regulatory cells within the CNS were below our detection limits or that the kinetics of T R cell homing was such that these cells may be detected within the CNS either earlier or later than currently measured. Chemokine gradients are an obvious mechanism that may regulate T R cell trafficking in vivo (8, 15) . In addition, T R homing may be influenced by differential expression of adhesion molecules. Our findings support this possibility, because T R cells expressed elevated levels of both ICAM-1 and P-selectin in comparison with non-T R cells (Fig. 4B) . The detection of P-selectin expression on T R cells was surprising, because previous reports have indicated that expression is limited to activated platelets and endothelium (16) . However, because P-selectin facilitates endothelium-T cell interactions (17) , P-selectin expression may prove to be one mechanism promoting the direct interaction of T R cells with target CD4 ϩ T cells in vivo. This is an attractive hypothesis in light of previous findings suggesting that T R cells must directly interact with target T cells to exert their suppressive phenotype and that P-selectin glycoprotein ligand-1 is expressed preferentially on Th1 cells (18) . This is supported by our recent studies showing that T R from P-selectin-deficient mice are functionally defective in vitro (data not shown). We are currently exploring the dependence of P-selectin/P-selectin glycoprotein ligand-1 interactions, as well as other adhesion molecules, in governing T R function both in vitro and in vivo.
